EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors

Table 2 Association between EGFR T790 M mutation and clinical features in patients with disease progression after receiving 1st generation EGFR TKI treatment

		EGFR T790M detected by any method			EGFR T790M detected by plama ctDNA ddPCR			T790M detected by cobas plama ctDNA test			Cobas Activating Mutation SQI		Cobas T790M SQI		ddPCR T790M quantitative
Characteristics	Total	Mutant	Wild type	P	Mutant	Wild type	P	Mutant	Wild type	P	Mean	P	Mean	P	Mean	P
Gender
Male	23	12	11	1	11	12	0.864	2	12	0.7	10.24	0.859	9.81	0.101	0.52	0.307
Female	46	24	22	1	21	25	0.864	8	25	0.7	10.55	0.859	8.17	0.101	1.4	0.307
Smoking status
Smoker	22	11	11	0.805	10	12	0.916	3	11	1	10.59	0.897	9.8	0.472	1.63	0.384
Non-smoker	47	25	22	0.805	22	25	0.916	7	26	1	10.37	0.897	7.94	0.472	0.86	0.384
Clinical Stage
IIIB	20	9	11	0.495	6	14	0.176	2	12	0.003	9.24	0.444	7.8	0.77	0.29	0.033
IVA	21	10	11		10	11		0	15		10.03		NA		0.2
IVB	28	17	11		16	12		8	10		11.51		8.68		2.37
M Stage
M1a	19	9	10	0.627	9	10	0.827	0	15	0.004	10.03	0.541	NA	NA	0.21	0.178
M1b	4	2	2		2	2		0	1		NA		NA		1.07
M1c	26	16	10		15	11		8	9		11.51		8.5		2.4
Time of EGFR-TKI treatment
≤ 6 months	14	6	8	0.733	6	8	0.952	1	6	0.621	10.5	0.082	8.99	0.203	0.83	0.472
6–12 months	26	14	12		12	14		5	12		12.71		10.32		1.75
>12 months	29	16	13		14	15		4	19		8.86		6.11		0.67

ddPCR Droplet Digital PCR, SQI Semi-Quantitative Index, Bold numbers showing statisticaly significant results

ISSN: 1746-1596